Related Experiment Video
Updated: Apr 26, 2026
08:43
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
14.4K
Intravesical therapy for superficial bladder cancer
1Department of Urology, Temple University Hospital, Philadelphia, Pennsylvania, USA.
Oncology (Williston Park, N.Y.)
|June 15, 2000
Summary
Superficial bladder cancer, or transitional cell carcinoma, requires intravesical therapy after transurethral resection to prevent recurrence. Bacillus Calmette-Guérin (BCG) and mitomycin are effective agents for prophylaxis and treatment.
Area of Science:
- Urology
- Oncology
- Pharmacology
Background:
- Transitional cell carcinoma of the bladder is a common cancer, with most tumors being superficial.
- Superficial bladder tumors carry a risk of recurrence and progression, necessitating adjuvant therapy.
- Transurethral resection is the primary treatment, often followed by intravesical agents.
Purpose of the Study:
- To review traditional and alternative intravesical agents for superficial transitional cell carcinoma of the bladder.
- To discuss agents for both therapy and prophylaxis against disease recurrence and progression.
- To highlight the efficacy of commonly used agents like bacillus Calmette-Guérin (BCG) and mitomycin.
Main Methods:
- Review of existing literature on intravesical therapies for superficial bladder cancer.
- Analysis of the efficacy of cytotoxic, immunomodulating, and photosensitizing agents.
- Examination of treatment strategies including doses, combinations, and schedules.
Main Results:
- Intravesical therapies, including cytotoxic and immunomodulating agents, are effective adjuncts to transurethral resection.
- Bacillus Calmette-Guérin (BCG) and mitomycin are the most commonly used and effective agents for prophylaxis.
- Valrubicin has FDA approval for refractory carcinoma in situ, but BCG and mitomycin remain standard for superficial disease.
Conclusions:
- Intravesical therapy plays a crucial role in managing superficial transitional cell carcinoma of the bladder.
- BCG and mitomycin are highly effective for preventing recurrence and progression of superficial bladder cancer.
- Ongoing research continues to explore new and existing intravesical agents for optimal patient outcomes.
Related Concept Videos
01:30Urinary Tract Calculi III: Medical Management
396
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
396
01:25Urinary Tract Calculi VI: Surgical Management
1.0K
Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...
1.0K
01:22Imaging Studies VI: Voiding Cystourethrography and Cystography
4.7K
Voiding Cystourethrography (VCUG) and Cystography are specialized radiographic procedures used to examine the structure and function of the bladder and urethra.Voiding Cystourethrography (VCUG)A Voiding Cystourethrogram (VCUG) is a diagnostic imaging procedure that assesses the anatomy and function of the lower urinary tract. It focuses on the bladder, bladder neck, and urethra, helping detect abnormalities such as vesicoureteral reflux (VUR)—the backward or reverse flow of urine into the...
4.7K